Eupraxia Pharmaceuticals Files 6-K Report

Ticker: EPRX · Form: 6-K · Filed: Apr 22, 2026 · CIK: 0001581178

Sentiment: neutral

Topics: foreign-issuer, regulatory-filing, press-release

TL;DR

Eupraxia Pharma dropped a 6-K filing today, check the press release for deets.

AI Summary

Eupraxia Pharmaceuticals Inc. filed a Form 6-K on April 22, 2026, reporting information as a foreign issuer. The filing includes a press release as Exhibit 99.1. The company's mailing and business address is located in Victoria, Canada.

Why It Matters

This filing provides updated information for investors and regulatory bodies regarding Eupraxia Pharmaceuticals' operations as a foreign issuer.

Risk Assessment

Risk Level: low — This is a routine foreign issuer report (6-K) and does not contain significant new financial or operational disclosures that would inherently increase risk.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign issuer required by the SEC, used to provide information that the issuer makes public in its home country or that is otherwise made public.

When was this Form 6-K filed and accepted by the SEC?

The filing date and acceptance date for this Form 6-K was April 22, 2026.

What is the CIK number for Eupraxia Pharmaceuticals Inc.?

The CIK number for Eupraxia Pharmaceuticals Inc. is 0001581178.

Where is Eupraxia Pharmaceuticals Inc. located?

Eupraxia Pharmaceuticals Inc.'s mailing and business address is 201-2067 CADBORO BAY RD. VICTORIA A1 V8R 5G4, indicating a location in Canada.

What is included as an exhibit in this filing?

Exhibit EX-99.1, a press release, is included in this Form 6-K filing.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on April 22, 2026 regarding EUPRAXIA PHARMACEUTICALS INC. (EPRX).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing